Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 1/20 | 0.40 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.40 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.40 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.40 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.40 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.38 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.36 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.36 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.36 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.36 |
| ▸ | GRIN2C | Q14957 | 1/20 | 0.36 |
| ▸ | GRIN3A | Q8TCU5 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.36 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14626766 | 0.85 | GRIN2D (0.48) | ALDH1A1CYP19A1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL1283404 | 0.82 | KDM4E (0.44) | KDM4EHRH3GRIN2DGRIN3BGRIN1 | |
| SCHEMBL1283784 | 0.81 | MAPT (0.37) | ALDH1A1KDM4EHRH3TDP1CYP19A1 | |
| SCHEMBL19325072 | 0.77 | GRIN2D (0.48) | ALDH1A1CYP19A1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL4987868 | 0.76 | S1PR4 (0.56) | ALDH1A1KDM4ETDP1CYP19A1MAPT | |
| SCHEMBL22888146 | 0.74 | LMNA (0.38) | ALDH1A1S1PR4L3MBTL1 | |
| SCHEMBL12328200 | 0.72 | GRIN2D (0.44) | ALDH1A1CYP19A1GRIN2DGRIN3BGRIN1 | |
| SCHEMBL972269 | 0.72 | PKM (0.41) | ALDH1A1KDM4ETDP1GRIN2DGRIN3B | |
| SCHEMBL1283794 | 0.72 | HRH3 (0.39) | ALDH1A1KDM4EHRH3TDP1GRIN2D | |
| SCHEMBL2889768 | 0.71 | KDM4E (0.51) | ALDH1A1KDM4EHRH3TDP1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120088778-A1 | AZOLE DERIVATIVES AND FUSED BICYCLIC AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | TRANSTECH PHARMA, INC. (US) | 2012-04-12 | — | — | US | disclosed |
| US-20100256119-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. | 2010-10-07 | — | — | US | disclosed |
| US-7737285-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2010-06-15 | — | — | US | disclosed |
| US-7714013-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2010-05-11 | — | — | US | disclosed |
| US-7361678-B2 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA, INC. (US) | 2008-04-22 | — | — | US | disclosed |
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-09-13 | — | — | US | disclosed |
| US-20070021386-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | TRANSTECH PHARMA (US) | 2007-01-25 | — | — | US | disclosed |
| EP-1482931-A2 | MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE | Transtech Pharma, Inc. (US) | 2004-12-08 | — | — | EP | disclosed |
| US-20040082542-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | VTV THERAPEUTICS LLC | 2004-04-29 | — | — | US | disclosed |
| WO-2003075921-A2 | MONO- AND BICYCLIC AZOLE DERIVATIVES THAT INHIBIT THE INTERACTION OF LIGANDS WITH RAGE | TRANSTECH PHARMA, INC. (US) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256119-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | PSEN1 335/4885PSEN2 401/4885APH1B 1099/4885 |
| US-20040082542-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | PSEN1 367/4885PSEN2 452/4885APH1B 1182/4885 |
| US-20070021386-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | PSEN1 360/4885PSEN2 464/4885APH1B 1037/4885 |
| US-20120088778-A1 | AZOLE DERIVATIVES AND FUSED BICYCLIC AZOLE DERIVATIVES AS THERAPEUTIC AGENTS | AGER, S100A4, S100B | PSEN1 360/4885PSEN2 464/4885APH1B 1037/4885 |
| US-20070213347-A1 | Azole derivatives and fused bicyclic azole derivatives as therapeutic agents | AGER, S100A4, S100B | PSEN1 360/4885PSEN2 464/4885APH1B 1037/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.